Taken together, these findings build upon specific aspects of the Amyloid Cascade Hypothesis (ACH) and point towards novel therapeutic strategies targeting lysosomal processing pathways that may hold promise for modulating both APP and tau pathology in AD. This evidence concerns the gene MAPT and Alzheimer disease.